Skip to main content
Midas Edge

HALOZYME THERAPEUTICS, INC.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

HALO$102.92-0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

Table of Contents

Item 6. Exhibits

3.1Amended and Restated Certificate of Incorporation of Halozyme Therapeutics, Inc. (filed as Exhibit 3.1 to the Company’s Form 8-K filed April 26, 2024 and incorporated herein by reference)
3.2The Company Bylaws, as amended (filed as Exhibit 3.1 to the Company’s Form 8-K filed April 24, 2026 and incorporated herein by reference)
4.1Indenture, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Company’s Form 8-K filed March 1, 2021 and incorporated herein by reference)
4.2Form of Note, dated March 1, 2021, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Company’s Form 8-K filed March 1, 2021 and incorporated herein by reference)
4.3Indenture, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Company’s Form 8-K filed August 18, 2022 and incorporated herein by reference)
4.4Form of Note, dated August 18, 2022, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (included within Exhibit 4.3) (filed as Exhibit 4.2 to the Company’s Form 8-K filed August 18, 2022 and incorporated herein by reference)
4.52031 Convertible Notes Indenture, dated November 12, 2025, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
4.6Form of 0% Convertible Senior Notes due 2031 (included within Exhibit 4.5) (filed as Exhibit 4.2 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
4.72032 Convertible Notes Indenture, dated November 12, 2025, between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.3 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
4.8Form of 0.875% Convertible Senior Notes due 2032 (included within Exhibit 4.7) (filed as Exhibit 4.4 to the Company’s Form 8-K filed November 12, 2025 and incorporated herein by reference)
4.9Convertible Notes Indenture, dated September 22, 2026 between Halozyme Therapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Company’s Form 8-K filed September 22, 2026 and incorporated herein by reference)
4.10Form of 1.50% Convertible Senior Notes due 2033 (included within Exhibit 4.1) (filed as Exhibit 4.2 to the Company’s Form 8-K filed September 22, 2026 and incorporated herein by reference)
10.1#Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan (filed herewith)
10.2Form of Capped Call Confirmation in connection with 1.50% Convertible Senior Notes due 2033 (filed as Exhibit 10.1 to the Company’s Form 8-K filed September 22, 2026 and incorporated herein by reference)
31.1Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended (filed herewith)
31.2Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended (filed herewith)
32Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101.INSInstance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document (filed herewith)
101.SCHInline Taxonomy Extension Schema Document (filed herewith)
101.CALInline Taxonomy Extension Calculation Linkbase Document (filed herewith)
101.DEFInline Taxonomy Extension Definition Linkbase Document (filed herewith)
101.LABInline Taxonomy Extension Label Linkbase Document (filed herewith)
101.PREInline Taxonomy Extension Presentation Linkbase Document (filed herewith)
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (filed herewith)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.